Login Register Cart 0
Generic placeholder image

Current Psychiatry Research and Reviews

Editor-in-Chief

ISSN (Print): 2666-0822
ISSN (Online): 2666-0830

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Prevalence of Comorbidities of Psychotic Disorders in Patients with Substance Use Disorders in Iran Psychiatric Hospital in Tehran, Iran

Author(s): Shiva Soraya, Hamidreza Ahmad Khaniha and Afsaneh Aminpour*

Volume 19, Issue 3, 2023

Published on: 13 October, 2022

Page: [291 - 301] Pages: 11

DOI: 10.2174/2666082218666220929113437

Price: $65

Abstract

Background: Substance use disorders are highly prevalent among psychotic patients and are associated with poorer clinical outcomes.

Objective: This study aimed to investigate the prevalence of psychotic disorders in substance users and the epidemiological features of this population.

Materials and Methods: In a cross-sectional study, we investigated 455 outpatient and inpatient participants with SUD referred to the Iran psychiatric hospital from April, 2020, to March, 2021. All participants were substance users, referred to Iran psychiatric center to follow up on their comorbidities and psychiatric disorders. The Structured Clinical Interview for DSM-5 (SCID) was used for psychotic disorders and substance use disorder diagnoses. Finally, gathered data were analyzed by SPSS-25.

Results: A total of 455 patients were involved in the study. The mean age was 34.66 years, of which 89.7% were men. The most common main substances include methamphetamine (39.1%) and heroin (27%). The prevalence of psychotic disorder was 36.7%, and the most common type was substance-induced psychotic disorder (26.4%) and schizophrenia (8.4%). There was a significant association between methamphetamine and opium use and the presence of substance-induced psychotic disorder and schizophrenia, respectively (p ˂ 0.001).

Conclusion: The most common type of substance use was methamphetamine, and the most common type of psychotic disorder was substance-induced psychotic disorder. There was a significant association between methamphetamine and opium use and the presence of substance- induced psychotic disorder and schizophrenia, respectively. It should be noted that this was a sample of individuals hospitalized for substance abuse. It was not a general population sample and was very biased toward substance use.

Keywords: substance use disorder, psychotic disorders, comorbidity

« Previous Next »
Graphical Abstract

[1]
Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of cooccurring addictive and mental disorders: Implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66(1): 17-31.
[http://dx.doi.org/10.1037/h0080151] [PMID: 8720638]
[2]
De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76(2-3): 135-57.
[http://dx.doi.org/10.1016/j.schres.2005.02.010] [PMID: 15949648]
[3]
Weich L, Pienaar W. Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa. Afr J Psychiatry 2009; 12(3): 213-7.
[http://dx.doi.org/10.4314/ajpsy.v12i3.48496] [PMID: 19750250]
[4]
Temmingh HS, Mall S, Howells FM, Sibeko G, Stein DJ. The prevalence and clinical correlates of substance use disorders in patients with psychotic disorders from an upper-middle-income country. S Afr J Psychiatry 2020; 26(1): 1473.
[http://dx.doi.org/10.4102/sajpsychiatry.v26i0.1473] [PMID: 32832129]
[5]
Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophr Bull 2010; 36(6): 1115-30.
[http://dx.doi.org/10.1093/schbul/sbp031] [PMID: 19386576]
[6]
Sara GE, Large MM, Matheson SL, et al. Stimulant use disorders in people with psychosis: A meta-analysis of rate and factors affecting variation. Aust N Z J Psychiatry 2015; 49(2): 106-17.
[http://dx.doi.org/10.1177/0004867414561526] [PMID: 25518844]
[7]
Centers for Disease Control and Prevention (CDC) Cigarette smoking among adults--United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54(44): 1121-4.
[PMID: 16280969]
[8]
Buckley PF, Brown ES. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry 2006; 67(7): e01.
[http://dx.doi.org/10.4088/JCP.0706e01] [PMID: 16961418]
[9]
Bennett ME, Bellack AS, Brown CH, DiClemente C. Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disorders. Addict Behav 2009; 34(10): 806-14.
[http://dx.doi.org/10.1016/j.addbeh.2009.03.023] [PMID: 19375237]
[10]
Destoop M, Docx L, Morrens M, Dom G. Meta-analysis on the effect of contingency management for patients with both psychotic disorders and substance use disorders. J Clin Med 2021; 10(4): 616.
[http://dx.doi.org/10.3390/jcm10040616] [PMID: 33561966]
[11]
Xie H, McHugo GJ, Fox MB, Drake RE. Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders. Psychiatr Serv 2005; 56(10): 1282-7.
[http://dx.doi.org/10.1176/appi.ps.56.10.1282] [PMID: 16215196]
[12]
Suokas JT, Perälä J, Suominen K, Saarni S, Lönnqvist J, Suvisaari JM. Epidemiology of suicide attempts among persons with psychotic disorder in the general population. Schizophr Res 2010; 124(1-3): 22-8.
[http://dx.doi.org/10.1016/j.schres.2010.09.009] [PMID: 20934306]
[13]
Schmidt LM, Hesse M, Lykke J. The impact of substance use disorders on the course of schizophrenia--A 15-year follow-up study: Dual diagnosis over 15 years. Schizophr Res 2011; 130(1-3): 228-33.
[http://dx.doi.org/10.1016/j.schres.2011.04.011] [PMID: 21592731]
[14]
Yücel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012; 38(2): 316-30.
[http://dx.doi.org/10.1093/schbul/sbq079] [PMID: 20660494]
[15]
Bertelsen RJ, Carlsen KCL, Calafat AM, et al. Urinary biomarkers for phthalates associated with asthma in Norwegian children. Environ Health Perspect 2013; 121(2): 251-6.
[http://dx.doi.org/10.1289/ehp.1205256] [PMID: 23164678]
[16]
Niemi PJA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: A register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry 2013; 74(1): e94-9.
[http://dx.doi.org/10.4088/JCP.12m07822] [PMID: 23419236]
[17]
Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. J Clin Psychiatry 2014; 75(4): 349-56.
[http://dx.doi.org/10.4088/JCP.13m08878] [PMID: 24813404]
[18]
Balderston R, Crockford DN. Management of the psychotic substance using patient. Can J Addict 2014; 5(2): 5-9.
[http://dx.doi.org/10.1097/02024458-201406000-00002]
[19]
Pereiro GC, Pino SCJ, Flórez MG, Arrojo RM, Becoña IE. Psychiatric comorbidity in patients from the addictive disorders assistance units of Galicia: The COPSIAD study. PLoS One 2013; 8(6): e66451.
[20]
McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101(10): 1473-8.
[http://dx.doi.org/10.1111/j.1360-0443.2006.01496.x] [PMID: 16968349]
[21]
Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB. Prevalence of psychotic symptoms in substance users: A comparison across substances. Compr Psychiatry 2009; 50(3): 245-50.
[http://dx.doi.org/10.1016/j.comppsych.2008.07.009] [PMID: 19374969]
[22]
Barry KL, Fleming MF, Greenley JR, Kropp S, Widlak P. Characteristics of persons with severe mental illness and substance abuse in rural areas. Psychiatr Serv 1996; 47(1): 88-90.
[http://dx.doi.org/10.1176/ps.47.1.88] [PMID: 8925354]
[23]
Comtois KA, Ries R, Armstrong HE. Case manager ratings of the clinical status of dually diagnosed outpatients. Psychiatr Serv 1994; 45(6): 568-73.
[http://dx.doi.org/10.1176/ps.45.6.568] [PMID: 8088736]
[24]
Mohammadkhani P, Forouzan AS, Hooshyari Z, Abasi I. Psychometric properties of Persian version of Structured Clinical Interview For Dsm-5-Research Version (SCID-5-RV): A diagnostic accuracy study. Iran J Psychiatry Behav Sci 2020; 14(2): e100930.
[http://dx.doi.org/10.5812/ijpbs.100930]
[25]
Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand 1992; 85(1): 48-55.
[http://dx.doi.org/10.1111/j.1600-0447.1992.tb01441.x] [PMID: 1546548]
[26]
Strålin P, Hetta J. Substance use disorders before, at and after first episode psychosis hospitalizations in a young national Swedish cohort. Drug Alcohol Depend 2020; 209: 107919.
[http://dx.doi.org/10.1016/j.drugalcdep.2020.107919] [PMID: 32113056]
[27]
Hamilton I, Monaghan M. Cannabis and psychosis: Are we any closer to understanding the relationship? Curr Psychiatry Rep 2019; 21(7): 48.
[http://dx.doi.org/10.1007/s11920-019-1044-x] [PMID: 31161275]
[28]
Crockford D, Addington D. Canadian schizophrenia guidelines: Schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry 2017; 62(9): 624-34.
[http://dx.doi.org/10.1177/0706743717720196] [PMID: 28886671]
[29]
Nielsen SM, Toftdahl NG, Nordentoft M, Hjorthøj C. Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: A nationwide population based register study. Psychol Med 2017; 47(9): 1668-77.
[http://dx.doi.org/10.1017/S0033291717000162] [PMID: 28166863]
[30]
Pasman JA, Verweij KJH, Gerring Z, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nat Neurosci 2018; 21(9): 1161-70.
[http://dx.doi.org/10.1038/s41593-018-0206-1] [PMID: 30150663]
[31]
Kaplan HI, Sadock BJ. Synopsis of psychiatry: Behavioral sciences clinical psychiatry. United States: Williams & Wilkins Co 1988.
[32]
McHugh RK, Votaw VR, Sugarman DE, Greenfield SF. Sex and gender differences in substance use disorders. Clin Psychol Rev 2018; 66: 12-23.
[http://dx.doi.org/10.1016/j.cpr.2017.10.012] [PMID: 29174306]
[33]
Khazaee PM, Pashaei T, Nouri R, Taymoori P, Ponnet K. Understanding the relapse process: Exploring Iranian women’s substance use experiences. Subst Abuse Treat Prev Policy 2019; 14(1): 27.
[http://dx.doi.org/10.1186/s13011-019-0216-3] [PMID: 31215472]
[34]
Taghva A, Farsi Z, Javanmard Y, Atashi A, Hajebi A, Khademi M. Stigma barriers of mental health in Iran: A qualitative study by stakeholders of mental health. Iran J Psychiatry 2017; 12(3): 163-71.
[PMID: 29062367]
[35]
Linscott RJ, Van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: On the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 2013; 43(6): 1133-49.
[http://dx.doi.org/10.1017/S0033291712001626] [PMID: 22850401]
[36]
Hosseini SH, Zarghami M, Moosavi SE, Nateghi GH, Masoudzadeh A. Study on the simultaneity of the substance abuse with psychiatric disorder in referred outpatients to psychiatryclinic of zare hospital for period of one year. J Mazandaran Univ Med Sci 2008; 18(67): 67-74.
[37]
Haghighi M, Yavarian R. Frequency of mental disorders in substance-abusing inpatients in Urmia psychiatric center. Nurs Midwifery J 2015; 13(6): 553-62.
[38]
Caton CLM, Drake RE, Hasin DS, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry 2005; 62(2): 137-45.
[http://dx.doi.org/10.1001/archpsyc.62.2.137] [PMID: 15699290]
[39]
Connell PH. Amphetamine Psychosis. BMJ 1957; 1(5018): 582.
[http://dx.doi.org/10.1136/bmj.1.5018.582]
[40]
Callaghan RC, Cunningham JK, Allebeck P, et al. Methamphetamine use and schizophrenia: A population-based cohort study in California. Am J Psychiatry 2012; 169(4): 389-96.
[http://dx.doi.org/10.1176/appi.ajp.2011.10070937] [PMID: 22193527]
[41]
Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev 2010; 29(4): 456-61.
[http://dx.doi.org/10.1111/j.1465-3362.2010.00196.x] [PMID: 20636664]
[42]
Maremmani AG, Rovai L, Rugani F, Bacciardi S, Dell’Osso L, Maremmani I. Substance abuse and psychosis. The strange case of opioids. Eur Rev Med Pharmacol Sci 2014; 18(3): 287-302.
[PMID: 24563427]
[43]
Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther 2018; 7(1): 13-21.
[http://dx.doi.org/10.1007/s40122-018-0097-6] [PMID: 29691801]
[44]
Watkins A, John A, Bradshaw C, Jones J, Jones M. Schizophrenia in high risk opioid users: A short communication on an autopsy study. Psychiatry Res 2019; 276: 112-4.
[http://dx.doi.org/10.1016/j.psychres.2019.04.026] [PMID: 31055116]
[45]
Addy PH, Radhakrishnan R, Cortes JA, D’Souza DC. Comorbid alcohol, cannabis, and cocaine use disorders in schizophrenia: Epidemiology, consequences, mechanisms, and treatment. Focus Am Psychiatr Publ 2012; 10(2): 140-53.
[http://dx.doi.org/10.1176/appi.focus.10.2.140]
[46]
Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS. Substance use in clinical high risk for psychosis: A review of the literature. Early Interv Psychiatry 2014; 8(2): 104-12.
[http://dx.doi.org/10.1111/eip.12100] [PMID: 24224849]
[47]
Carney R, Cotter J, Bradshaw T, Firth J, Yung AR. Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis. Schizophr Res 2016; 170(2-3): 290-300.
[http://dx.doi.org/10.1016/j.schres.2016.01.010] [PMID: 26794596]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy